0001209191-23-027190.txt : 20230503
0001209191-23-027190.hdr.sgml : 20230503
20230503200454
ACCESSION NUMBER: 0001209191-23-027190
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230501
FILED AS OF DATE: 20230503
DATE AS OF CHANGE: 20230503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ticho Barry
CENTRAL INDEX KEY: 0001780088
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38938
FILM NUMBER: 23885974
MAIL ADDRESS:
STREET 1: C/O STOKE THERAPEUTICS, INC.
STREET 2: 45 WIGGINS AVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Stoke Therapeutics, Inc.
CENTRAL INDEX KEY: 0001623526
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471144582
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-430-8200
MAIL ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141028
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-01
0
0001623526
Stoke Therapeutics, Inc.
STOK
0001780088
Ticho Barry
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD
MA
01730
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-05-01
4
S
0
24967
10.0039
D
86758
D
Common Stock
2023-05-02
4
S
0
5513
10.0007
D
81245
D
Common Stock
2023-05-03
4
S
0
24697
10.1375
D
56548
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Stephen Tulipano, Attorney-in-Fact
2023-05-03